Terms: = Lung cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR
582 results:
1. Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer.
Li Y; Sharma A; Schmidt-Wolf IGH
Mol Cancer; 2024 Apr; 23(1):80. PubMed ID: 38659003
[TBL] [Abstract] [Full Text] [Related]
2. Implantable car T cell factories enhance solid tumor treatment.
Pandit S; Agarwalla P; Song F; Jansson A; Dotti G; Brudno Y
Biomaterials; 2024 Jul; 308():122580. PubMed ID: 38640784
[TBL] [Abstract] [Full Text] [Related]
3. Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses.
Tapia-Galisteo A; Sánchez-Rodríguez I; Narbona J; Iglesias-Hernández P; Aragón-García S; Jiménez-Reinoso A; Compte M; Khan S; Tsuda T; Chames P; Lacadena J; Álvarez-Vallina L; Sanz L
Oncoimmunology; 2024; 13(1):2338558. PubMed ID: 38623463
[TBL] [Abstract] [Full Text] [Related]
4. Universal car T cells targeted to HER2 with a biotin-trastuzumab soluble linker penetrate spheroids and large tumor xenografts that are inherently resistant to trastuzumab mediated ADCC.
Nagy L; Mezősi-Csaplár M; Rebenku I; Vereb G; Szöőr Á
Front Immunol; 2024; 15():1365172. PubMed ID: 38562932
[TBL] [Abstract] [Full Text] [Related]
5. Anti-CD30 car T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30
Grover NS; Hucks G; Riches ML; Ivanova A; Moore DT; Shea TC; Seegars MB; Armistead PM; Kasow KA; Beaven AW; Dittus C; Coghill JM; Jamieson KJ; Vincent BG; Wood WA; Cheng C; Morrison JK; West J; Cavallo T; Dotti G; Serody JS; Savoldo B
Lancet Haematol; 2024 May; 11(5):e358-e367. PubMed ID: 38555923
[TBL] [Abstract] [Full Text] [Related]
6. The prognostic value and model construction of inflammatory markers for patients with non-small cell lung cancer.
Xu W; Liu X; Yan C; Abdurahmane G; Lazibiek J; Zhang Y; Cao M
Sci Rep; 2024 Mar; 14(1):7568. PubMed ID: 38555313
[TBL] [Abstract] [Full Text] [Related]
7. lung cancer Prevalence in Virginia: A Spatial Zipcode-Level Analysis via INLA.
Sahoo I; Zhao J; Deng X; Cockburn MG; Tossas K; Winn R; Bandyopadhyay D
Curr Oncol; 2024 Feb; 31(3):1129-1144. PubMed ID: 38534917
[TBL] [Abstract] [Full Text] [Related]
8. Drug-induced interstitial lung disease: a narrative review of a clinical conundrum.
Harrison M; Kavanagh G; Corte TJ; Troy LK
Expert Rev Respir Med; 2024; 18(1-2):23-39. PubMed ID: 38501199
[TBL] [Abstract] [Full Text] [Related]
9. cancer-oocyte SAS1B protein is expressed at the cell surface of multiple solid tumors and targeted with antibody-drug conjugates.
Mandal A; Shetty J; Tran CA; Olson WC; Mandal M; Ban B; Pires ES; Adair SJ; Bauer TW; Slingluff CL; Herr JC
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485187
[TBL] [Abstract] [Full Text] [Related]
10. [Severe complications of systemic treatment in thoracic oncology].
Berghmans T; Brandão M; Ilzkovitz M; Meert AP
Rev Mal Respir; 2024 Apr; 41(4):317-324. PubMed ID: 38461088
[TBL] [Abstract] [Full Text] [Related]
11. Targeting the activated microenvironment with endosialin (CD248)-directed car-T cells ablates perivascular cells to impair tumor growth and metastasis.
Ash SL; Orha R; Mole H; Dinesh-Kumar M; Lee SP; Turrell FK; Isacke CM
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38413223
[TBL] [Abstract] [Full Text] [Related]
12. Rejuvenated iPSC-derived GD2-directed carT Cells Harbor Robust Cytotoxicity Against Small Cell lung cancer.
Kinoshita S; Ishii M; Ando J; Kimura T; Yamaguchi T; Harada S; Takahashi F; Nakashima K; Nakazawa Y; Yamazaki S; Ohshima K; Takahashi K; Nakauchi H; Ando M
Cancer Res Commun; 2024 Mar; 4(3):723-737. PubMed ID: 38380966
[TBL] [Abstract] [Full Text] [Related]
13. Targeting Antheraea pernyi silk fibroin modified dual-gene coexpressing vector enhances gene transport and promotes lung tumor suppression.
Qu J; Xia Z; Liu Y; Li M; Xie Y
Int J Biol Macromol; 2024 Mar; 262(Pt 2):130074. PubMed ID: 38342259
[TBL] [Abstract] [Full Text] [Related]
14. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host.
Zhou R; Wu ST; Yazdanifar M; Williams C; Sanders A; Brouwer C; Maher J; Mukherjee P
J Immunother; 2024 Apr; 47(3):77-88. PubMed ID: 38270462
[TBL] [Abstract] [Full Text] [Related]
15. T cell lymphoma and secondary primary malignancy risk after commercial car T cell therapy.
Ghilardi G; Fraietta JA; Gerson JN; Van Deerlin VM; Morrissette JJD; Caponetti GC; Paruzzo L; Harris JC; Chong EA; Susanibar Adaniya SP; Svoboda J; Nasta SD; Ugwuanyi OH; Landsburg DJ; Fardella E; Waxman AJ; Chong ER; Patel V; Pajarillo R; Kulikovskaya I; Lieberman DB; Cohen AD; Levine BL; Stadtmauer EA; Frey NV; Vogl DT; Hexner EO; Barta SK; Porter DL; Garfall AL; Schuster SJ; June CH; Ruella M
Nat Med; 2024 Apr; 30(4):984-989. PubMed ID: 38266761
[TBL] [Abstract] [Full Text] [Related]
16. Co-expression of IL-21-Enhanced NKG2D car-NK cell therapy for lung cancer.
Zhang Y; Zhang C; He M; Xing W; Hou R; Zhang H
BMC Cancer; 2024 Jan; 24(1):119. PubMed ID: 38263004
[TBL] [Abstract] [Full Text] [Related]
17. Folate Receptor Alpha-A Novel Approach to cancer Therapy.
Gonzalez T; Muminovic M; Nano O; Vulfovich M
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256120
[TBL] [Abstract] [Full Text] [Related]
18. Tumor resistance to anti-mesothelin car-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.
Liu XF; Onda M; Schlomer J; Bassel L; Kozlov S; Tai CH; Zhou Q; Liu W; Tsao HE; Hassan R; Ho M; Pastan I
Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2317283121. PubMed ID: 38227666
[TBL] [Abstract] [Full Text] [Related]
19. AuNPs/cnc Nanocomposite with A "Dual Dispersion" Effect for LDI-TOF MS Analysis of Intact Proteins in NSCLC Serum Exosomes.
Shan L; Qiao Y; Ma L; Zhang X; Chen C; Xu X; Li D; Qiu S; Xue X; Yu Y; Guo Y; Qian K; Wang J
Adv Sci (Weinh); 2024 Mar; 11(12):e2307360. PubMed ID: 38224220
[TBL] [Abstract] [Full Text] [Related]
20. Efficacy against lung cancer Is Augmented by Combining Aberrantly N-Glycosylated T Cells with a Chimeric Antigen Receptor Targeting Fragile X Mental Retardation 1 Neighbor.
Toyofuku T; Ishikawa T; Nojima S; Kumanogoh A
J Immunol; 2024 Mar; 212(5):917-927. PubMed ID: 38214607
[TBL] [Abstract] [Full Text] [Related]
[Next]
